Seroprevalence of viral infectious diseases and associated factors in Korean patients with inflammatory bowel diseases

키워드

참고문헌 (50)

1. 이승훈, "Immunological pathogenesis of inflammatory bowel disease", Intestinal research, 16(1), pp.26~42 (2018), 대한장연구학회
2. Zenlea T, "Immunosuppressive therapies for inflammatory bowel disease", World J Gastroenterol, 20, pp.3146~3152 (2014)
3. Rahier JF, "Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease", J Crohns Colitis, 8, pp.443~468 (2014)
4. Bonovas S, "Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease : a systematic review and network meta-analysis", Clin Gastroenterol Hepatol, 14, pp.1385~1397 (2016)
5. Ananthakrishnan AN, "Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases", J Crohns Colitis, 7, pp.107~112 (2013)
6. Reich J, "Vaccinating patients with inflammatory bowel disease", Gastroenterol Hepatol(N Y), 12, pp.540~546 (2016)
7. Cullen G, "Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease", Gut, 61, pp.385~391 (2012)
8. Lee CK, "Patients with Crohn’s disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine", J Crohns Colitis, 8, pp.384~391 (2014)
9. Park SH, "Efficacy of hepatitis A vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease", Inflamm Bowel Dis, 20, pp.69~74 (2014)
10. DeBruyn J, "Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy : a randomized trial", Inflamm Bowel Dis, 22, pp.638~647 (2016)
11. Wasan SK, "Herpes zoster vaccine response in inflammatory bowel disease patients on low-dose immunosuppression", Inflamm Bowel Dis, 22, pp.1391~1396 (2016)
12. DeBruyn JC, "Serologic status of routine childhood vaccines, cytomegalovirus, and Epstein-Barr virus in children with inflammatory bowel disease", Inflamm Bowel Dis, 25, pp.1218~1226 (2019)
13. Sands BE, "Guidelines for immunizations in patients with inflammatory bowel disease", Inflamm Bowel Dis, 10, pp.677~692 (2004)
14. Farraye FA, "ACG clinical guideline : preventive care in inflammatory bowel disease", Am J Gastroenterol, 112, pp.241~258 (2017)
15. Inflammatory Bowel Disease Group, "Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication)", Intestinal research, 16(2), pp.178~193 (2018), 대한장연구학회
16. Sitki-Green DL, "Biology of Epstein-Barr virus during infectious mononucleosis", J Infect Dis, 189, pp.483~492 (2004)
17. Beaugerie L, "Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease : a prospective observational cohort study", Lancet, 374, pp.1617~1625 (2009)
18. Beaugerie L, "Lymphoma : the bête noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease", Gastroenterology, 145, pp.927~930 (2013)
19. Lemaitre M, "Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease", JAMA, 318, pp.1679~1686 (2017)
20. De Francisco R, "Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease", Aliment Pharmacol Ther, 48, pp.723~730 (2018)
21. Cleveland NK, "Many inflammatory bowel disease patients are not immune to measles or pertussis", Dig Dis Sci, 61, pp.2972~2976 (2016)
22. Naganuma M, "Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD", Inflamm Bowel Dis, 19, pp.418~422 (2013)
23. "LIAISON® Measles IgG" (2021)[URL]
24. "LIAISON® Mumps IgG" (2021)[URL]
25. "LIAISON® Rubella IgG II" (2021)[URL]
26. "LIAISON® VZV IgG" (2021)[URL]
27. "Epstein-barr virus, VCA IgG, EBNA IgG, EBV IgM, EA IgG" (2021)[URL]
28. "Elecsys Anti-HAV" (2020)[URL]
29. Kim SS, "Sero-epidemiology of measles and mumps in Korea : impact of the catch-up campaign on measles immunity", Vaccine, 23, pp.290~297 (2004)
30. Yang TU, "Resurgence of measles in a country of elimination : interim assessment and current control measures in the Republic of Korea in early 2014", Int J Infect Dis, 33, pp.12~14 (2015)
31. Choe YJ, "Measles elimination activities in the Western Pacific region : experience from the Republic of Korea", J Korean Med Sci, 30(Suppl 2), pp.S115~S121 (2015)
32. 최영준, "Current status of measles in the Republic of Korea: an overview of case-based and seroepidemiological surveillance scheme", Clinical and Experimental Pediatrics, 55(12), pp.455~461 (2012), 대한소아청소년과학회
33. Kang HJ, "An increasing, potentially measles-susceptible population over time after vaccination in Korea", Vaccine, 35, pp.4126~4132 (2017)
34. 정지원, "Seroprevalence of Measles in Healthcare Workers in South Korea", Infection and Chemotherapy, 51(1), pp.58~61 (2019), 대한감염학회[DOI]
35. Paunio M, "Secondary measles vaccine failures identified by measurement of IgG avidity : high occurrence among teenagers vaccinated at a young age", Epidemiol Infect, 124, pp.263~271 (2000)
36. Pena-Rey I, "Measles risk groups in Spain : implications for the European measles-elimination target", Vaccine, 27, pp.3927~3934 (2009)
37. Emek M, "Association between seroprevalence of measles and various social determinants in the year following a measles outbreak in Turkey", Public Health, 147, pp.51~58 (2017)
38. Smetana J, "Decreasing seroprevalence of measles antibodies after vaccination : possible gap in measles protection in adults in the Czech Republic", PLoS One, 12, pp.e0170257~ (2017)
39. Lebo EJ, "Seroprevalence of measles, mumps, rubella and varicella antibodies in the United States population, 2009-2010", Open Forum Infect Dis, 2, pp.ofv006~ (2015)
40. MoranKi, "Rubella Seroprevalence in Korean Children", Journal of Korean Medical Science, 18(3), pp.331~336 (2003), 대한의학회
41. Jeong KP, "Prevalence of rubella antibodies in the Southern Central Korea", J Korean Pediatr Soc, 38, pp.786~793 (1995)
42. LeBaron CW, "Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine", J Infect Dis, 200, pp.888~899 (2009)
43. 이현주, "Seroepidemiology of Varicella-Zoster Virus in Korea", Journal of Korean Medical Science, 28(2), pp.195~199 (2013), 대한의학회
44. 이현주, "Seroepidemiology of Hepatitis A in Korea: Changes over the Past 30 Years", Journal of Korean Medical Science, 26(6), pp.791~796 (2011), 대한의학회
45. Kim KA, "Nationwide seropositivity of hepatitis A in Republic of Korea from 2005 to 2014, before and after the outbreak peak in 2009", PLoS One, 12, pp.e0170432~ (2017)
46. Lednar WM, "Frequency of illness associated with epidemic hepatitis A virus infections in adults", Am J Epidemiol, 122, pp.226~233 (1985)
47. Yoon JG, "Seroprevalence and disease burden of acute hepatitis A in adult population in South Korea", PLoS One, 12, pp.e0186257~ (2017)
48. Heo JY, "Low level of immunity against hepatitis A among Korean adolescents : vaccination rate and related factors", Am J Infect Control, 41, pp.e97~e100 (2013)
49. Smatti MK, "Epstein-Barr virus epidemiology, serology, and genetic variability of LMP-1 oncogene among healthy population : an update", Front Oncol, 8, pp.211~ (2018)
50. Caldera F, "Immunosuppression does not affect antibody concentrations to measles, mumps, and rubella in patients with inflammatory bowel disease", Dig Dis Sci, 64, pp.189~195 (2019)

관련 논문AI추천